Premium
Prognostic value of concentration of pregnancy‐specific β 1 ‐glycoprotein (SP1) in serum of patients with breast cancer
Author(s) -
Fagnart O. C.,
Cambiaso C. L.,
Lejeune M. D.,
Noel G.,
Maisin H.,
Masson P. L.
Publication year - 1985
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910360504
Subject(s) - medicine , breast cancer , stage (stratigraphy) , gastroenterology , mammary gland , pregnancy , glycoprotein , cancer , estrogen , gynecology , oncology , endocrinology , biology , paleontology , genetics , microbiology and biotechnology
Pregnancy‐specific β 1 ‐glycoprotein (SP1) was assayed by particle counting immunoassay in serum from 46 healthy female blood donors, 33 patients with benign mastopathy and 84 patients with breast cancer before operation and during follow‐up. Values > I μg/I were found more frequently with benign mastopathies (11/33) and in patients with breast cancer at stage 2 (20/48), 3 (4/9), and 4 (7/10) than in healthy female blood donors (3/46). The survival rate after 4 years was significantly lower in patients with SP1 level > 1 μg/1 before tumor resection (52% vs. 87%). The difference remained significant when only patients in stage 2 were taken into account (57% vs. 85%). A highly significant (r = 0.64; N = 46) negative correlation was observed between the concentration of SP1 in serum and the concentration of estrogen receptor in the tumor. The longitudinal study of patients in stage 2 indicated that, of the 15 whose SP1 concentration fell below 1 μg/1 after operation, 14 survived over 4 years whereas during the same period, 9 of the 10 patients whose SP1 value remained higher than I μg/1 died.